Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

65.60 +0.30 (+0.46%)
Streaming Delayed Price Updated: 2:45 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Monopar Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 10/21- 10/25
Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatility 
Via MarketBeat
Topics Artificial Intelligence Economy Stocks
News headline image
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug. 
Via MarketBeat
News headline image
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.